International Journal of Clinical Oncology

, Volume 24, Issue 3, pp 306–312 | Cite as

Ureteral stents for malignant extrinsic ureteral obstruction: outcomes and factors predicting stent failure

  • Hiroshi MatsuuraEmail author
  • Shigeki Arase
  • Yasuhide Hori
Original Article



This study investigated the clinical outcomes of stent placement for malignant extrinsic ureteral obstruction (MUO) and predictive factors for stent failure.


We retrospectively analyzed clinical data for 91 patients with radiologically significant hydronephrosis due to MUO who underwent successful stent placement. In total, 132 ureters were stented for the decompression. Factors related to stent failure were analyzed with a Cox proportional hazards model.


Stent failure occurred in 25 ureters in 20 patients. The median interval to failure was 63 days. The multivariate analysis showed that the significant predictors of stent failure were bladder invasion and severe hydronephrosis before the stent insertion. The patients were divided into three groups based on these two factors: low-risk (neither factor; 85 patients), intermediate-risk (one factor; 37), and high-risk (both factors; 10). The median stent failure-free survival rate at 3 months was 94.8% in the low-risk, 71.8% in the intermediate-risk and 55.6% in the high-risk group, respectively. Of the ureters with stent failure, there was successful re-replacement of internal stents in 3 low-risk, 6 intermediate-risk and no high-risk ureters. Replacement by nephrostomy was done in 2 low-risk, 5 intermediate-risk and 7 high-risk ureters.


The patients considered at low-risk could be managed without stent failure by internal stenting. However, the patients at high-risk may require the consideration of nephrostomy or other alternatives as the initial treatment. Our stratification model may allow better risk stratification for patients with regard to ureteral stenting, helping to identify patients for whom ureteral stenting is indicated.


Malignant extrinsic ureteral obstruction Ureteral stent Predictive factors Stent failure 


Compliance with standards

Conflict of interest

There are no conflicts of interest to declare.


  1. 1.
    Elsamra SE, Leavitt DA, Motato HA et al (2015) Stenting for malignant ureteral obstruction: Tandem, metal or metal-mesh stents. Int J Urol 22:629–636CrossRefPubMedGoogle Scholar
  2. 2.
    Ganatra AM, Loughlin KR (2005) The management of malignant ureteral obstruction treated with ureteral stents. J Urol 174:2125–2128CrossRefPubMedGoogle Scholar
  3. 3.
    Fiuk J, Bao Y, Calleary JG et al (2015) The use of internal stents in chronic ureteral obstruction. J Urol 193:1092–1100. (Epub 2014 Nov) CrossRefPubMedGoogle Scholar
  4. 4.
    Pavlovic K, Lange D, Chew BH (2016) Stents for malignant ureteral obstruction. Asian J Urol 3:142–149CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Sountoulides P, Mykoniatis I, Dimasis N (2014) Palliative management of malignant upper urinary tract obstruction. Hippokratia 18:292–297PubMedPubMedCentralGoogle Scholar
  6. 6.
    Kamiyama Y, Matsuura S, Kato M et al (2011) Stent failure in the management of malignant extrinsic ureteral obstruction: Risk factors. Int J Urol 18:379–382CrossRefPubMedGoogle Scholar
  7. 7.
    Izumi K, Mizokami A, Maeda Y et al (2011) Current outcome of patients with ureteral stents for the management of malignant ureteral obstruction. J Urol 185:556–561CrossRefPubMedGoogle Scholar
  8. 8.
    Yossepowitch O, Lifshitz DA, Dekel Y et al (2001) Predicting the success of retrograde stenting for managing ureteral obstruction. J Urol 66:1746–1749CrossRefGoogle Scholar
  9. 9.
    Ishioka J, Kageyama Y, Inoue M et al (2008) Prognostic model for predicting survival after palliative urinary diversion for ureteral obstruction: analysis of 140 cases. J Urol 180:618–621CrossRefPubMedGoogle Scholar
  10. 10.
    Cordeiro MD, Coelho RF, Chade DC et al (2016) A prognostic model for survival after palliative urinary diversion for malignant ureteric obstruction: a prospective study of 208 patients. BJU Int 117:266–271CrossRefPubMedGoogle Scholar
  11. 11.
    Hsu L, Li H, Pucheril D et al (2016) Use of percutaneous nephrostomy and ureteral stenting in management of ureteral obstruction. World J Nephrol 5:172–181CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Alawneh A, Tuqan W, Innabi A et al (2016) Clinical factors associated with a short survival time after percutaneous nephrostomy for ureteric obstruction in cancer patients: an updated model. J Pain Symptom Manage 251:255–261CrossRefGoogle Scholar
  13. 13.
    Wang JY, Zhang HL, Zhu Y, (2016) Predicting the failure of retrograde ureteral stent insertion for managing malignant ureteral obstruction in outpatients. Oncol Lett 11:879–883CrossRefPubMedGoogle Scholar
  14. 14.
    Shekarriz B, Shekarriz H, Upadhyay J et al (1999) Outcome of palliative urinary diversion in the treatment of advanced malignancies. Cancer 85:998–1003CrossRefPubMedGoogle Scholar
  15. 15.
    Chung SY, Stein RJ, Landsittel D et al (2004) 15-Year experience with the management of extrinsic ureteral obstruction with indwelling ureteral stents. J Urol 172:592–595CrossRefPubMedGoogle Scholar
  16. 16.
    Fiuk J, Bao Y, Calleary JG et al (2015) The use of internal stents in chronic ureteral obstruction. J Urol 193:1092–1100CrossRefPubMedGoogle Scholar
  17. 17.
    McCullough TC, May NR, Metro MJ et al (2008) Serum creatinine predicts success in retrograde ureteral stent placement in patients with pelvic malignancies. Urology 72:370–373CrossRefPubMedGoogle Scholar
  18. 18.
    Wenzler DL, Kim SP, Rosevear HM et al (2008) Success of ureteral stents for intrinsic ureteral obstruction. J Endourol 22:295–299CrossRefPubMedGoogle Scholar
  19. 19.
    Yu SH, Ryu JG, Jeong SH et al (2013) Predicting factors for stent failure-free survival in patients with a malignant ureteral obstruction managed with ureteral stents. Korean J Urol 54:316–321CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Zadra JA, Jewett MA, Keresteci AG et al (1987) Nonoperative urinary diversion for malignant ureteral obstruction. Cancer 60:1353–1357CrossRefPubMedGoogle Scholar
  21. 21.
    Kallidonis PS, Georgiopoulos IS, Kyriazis ID et al (2015) The full metallic double-pigtail ureteral stent: Review of the clinical outcome and current status. Indian J Urol 31:8–14CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Baumgarten AS, Hakky TS, Carrion RE et al (2014) A single-institution experience with metallic ureteral stents: a cost-effective method of managing deficiencies in ureteral drainage. Int Braz J Urol 40:225–231CrossRefPubMedGoogle Scholar
  23. 23.
    Ficko Z, Hyams ES (2018) Complications of upper tract drainage. In: Samir S, Taneja MD, Ojas Shah MD (eds) Complications of urologic surgery, 5th edn. Elsevier, New York, pp 218–225Google Scholar
  24. 24.
    Chow PM, Chiang IN, Chen CY et al (2015) Malignant ureteral obstruction: Functional duration of metallic versus polymeric ureteral stents. PLoS One 10:e0135566CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2018

Authors and Affiliations

  1. 1.Department of UrologyMie Prefectural General Medical CenterYokkaichiJapan
  2. 2.Department of UrologyKameyama Nephro-Urological ClinicKameyamaJapan

Personalised recommendations